Quantcast

Latest Clinical trial Stories

2014-05-27 08:27:36

SYDNEY and BEDMINSTER, N.J., May 27, 2014 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the United States Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Moxduo New Drug Application (NDA) for the treatment of moderate to severe acute pain. The Agency stated that there was not sufficient evidence to support approval of Moxduo at this time. The Agency indicated clinical information demonstrating a clear...

2014-05-27 04:21:46

BLUE BELL, Pa., May 27, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its 90%-owned subsidiary, VGX Animal Health, Inc. (VAH), has concluded an agreement for the sale of its animal health assets to Plumbline Life Sciences, Inc. (PLS) of Korea. The assets being transferred include an exclusive license with Inovio for animal applications of its growth hormone-releasing hormone (GHRH) technology and animal DNA vaccines plus a non-exclusive license...

2014-05-23 12:24:34

WASHINGTON, May 23, 2014 /PRNewswire-USNewswire/ -- In March of this year, a team of Georgetown University scientists published research showing that, for the first time ever, a blood test has the potential to predict Alzheimer's disease before patients start showing symptoms. AACC is pleased to announce that a late-breaking session at the 2014 AACC Annual Meeting & Clinical Lab Expo in Chicago will expand upon this groundbreaking research and discuss why it could be the key to...

2014-05-23 04:20:51

BLUE BELL, Pa., May 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that at the Company's Annual General Meeting held May 22, 2014, the Company's shareholders approved the proposal of a reverse split of the Company's common stock. The Company's Board of Directors subsequently approved the immediate implementation of a 1-for-4 reverse stock split of Inovio's common stock, where each 4 shares of issued and outstanding common stock and equivalents...

2014-05-22 23:11:58

Researchers, pharmaceutical companies, advocacy organizations and healthcare providers can access large sets of patient-provided de-identified data to speed research. San Mateo, Calif. (PRWEB) May 22, 2014 PatientCrossroads, pioneer of the groundbreaking CONNECT patient registry platform, has expanded the open availability of disease-specific patient data with the launch of its CONNECT Data Portal. The Data Portal allows any authorized user to see the de-identified patient data that has...

2014-05-22 23:04:58

RnRMarketResearch.com adds “Diabetic Peripheral Neuropathy Global Clinical Trials Review, H1, 2014” to its store. Order a purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=179159. Dallas, Texas (PRWEB) May 22, 2014 This report provides comprehensive information on the therapeutic development for Diabetic Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of...

2014-05-22 08:31:11

SAN FRANCISCO, May 22, 2014 /PRNewswire/ -- PULSE enables highly customized IRT trial design while maintaining endpoint's signature 30-Day delivery timeline endpoint Clinical, Inc., a leading provider of Interactive Response Technology (IRT) systems via phone (IVRS), web (IWRS) and mobile (IMRS) for global clinical trials, today announced the launch of its next-generation PULSE 3.0 platform. The enhanced PULSE platform provides highly customized configuration and...

2014-05-21 13:45:48

American Thoracic Society Reminders prompting asthma patients to take their control inhalers if they miss a dose significantly improve medication adherence, according to a primary-care based study conducted by a research team in Australia. In this six-month investigation, patients receiving reminders took on average 73% of their prescribed doses compared to only 46% in patients who did not have reminders. The results of the cluster randomized controlled trial were presented at the ATS...

2014-05-21 08:29:59

RYE, N.Y., May 21, 2014 /PRNewswire/ -- Curemark, a leading drug research and development company focused on the treatment of neurological and other diseases, announced today that the company was named a Red Herring Top 100 North American award-winner. "We believe that Curemark embodies the vision, drive, and innovation that define a successful entrepreneurial venture. Curemark should be proud of its accomplishment as the competition was very strong," stated Alex Vieux, published...

2014-05-21 08:29:17

- On Track for Study Participation in Major HCC Markets Worldwide - LAWRENCEVILLE, N.J., May 21, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced it has received regulatory clearance to initiate its Phase III OPTIMA Study at clinical trial sites in Taiwan, Hong Kong, South Korea and Canada. The OPTIMA Study is the Company's planned global pivotal, double-blind, placebo-controlled study evaluating ThermoDox®, its proprietary heat-activated liposomal...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.